Vir Biotechnology: Funding, Investors & Team (Oct 2026)
Vir Biotechnology leverages the immense potential of the immune system to address critical unmet medical needs and improve patient outcomes Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and the PRO-XTEN™ protease-releasable masking technology in infectious diseases and cancer, respectively. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in infectious diseases, with a leading program in chronic hepatitis delta, are complemented by strategic programs in oncology. We have broken ground in immunology, demonstrating our ability to discover, engineer and develop antibody-based medicines for two of the greatest health challenges of our time: COVID-19 and Ebola. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients.
Vir Biotechnology has raised $150M across 1 funding round on record, the most recent an undisclosed round of $150M announced in Feb 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Vir Biotechnology Company Profile and Key Stats
Latest funding round on record: Feb 2026.
Vir Biotechnology Funding Rounds
Vir Biotechnology Founders and Leadership Team
No contact details are on record for this team yet.
Vir Biotechnology Funding Compared to Other Biotechnology Startups
Vir Biotechnology's latest round of $150M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Vir Biotechnology in Biotechnology and San Francisco
Companies Similar to Vir Biotechnology
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Vir Biotechnology Funding FAQs
What does Vir Biotechnology do?
Vir Biotechnology leverages the immense potential of the immune system to address critical unmet medical needs and improve patient outcomes Our pipeline is built on two technology platforms which enable us to rapidly identify, optimize and advance candidates from concepts to the clinic: our next-generation antibody platform and the PRO-XTEN™ protease-releasable masking technology in infectious diseases and cancer, respectively. We focus on the therapeutic areas in which we believe we can most benefit patients. Our foundational efforts in infectious diseases, with a leading program in chronic hepatitis delta, are complemented by strategic programs in oncology. We have broken ground in immunology, demonstrating our ability to discover, engineer and develop antibody-based medicines for two of the greatest health challenges of our time: COVID-19 and Ebola. Every day, we work with the utmost urgency to deliver potentially transformative medicines for patients.
How much funding has Vir Biotechnology raised?
Vir Biotechnology has raised $150M across 1 round on record. The most recent is an undisclosed round of $150M announced in Feb 2026.
When did Vir Biotechnology last raise funding?
Vir Biotechnology's most recent funding round on record is an undisclosed round of $150M, announced in Feb 2026.
Who founded Vir Biotechnology?
FundedIQ lists Klaus Frueh (Founder) at Vir Biotechnology.
Where is Vir Biotechnology headquartered?
Vir Biotechnology is based in San Francisco, California, United States.
How many employees does Vir Biotechnology have?
Vir Biotechnology is in the 251-500 employee band.
How does Vir Biotechnology's funding compare to other Biotechnology startups?
Vir Biotechnology's latest round of $150M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Vir Biotechnology Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Vir Biotechnology is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.